eprintid: 10186117
rev_number: 6
eprint_status: archive
userid: 699
dir: disk0/10/18/61/17
datestamp: 2024-01-26 11:49:33
lastmod: 2024-01-26 11:49:33
status_changed: 2024-01-26 11:49:33
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Toorop, Alyssa A
creators_name: Noteboom, Samantha
creators_name: Steenwijk, Martijn D
creators_name: Gravendeel, Job W
creators_name: Jasperse, Bas
creators_name: Barkhof, Frederik
creators_name: Strijbis, Eva Mm
creators_name: Rispens, Theo
creators_name: Schoonheim, Menno M
creators_name: van Kempen, Zoé LE
creators_name: Killestein, Joep
title: Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis
ispublished: inpress
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F82
keywords: Multiple sclerosis, brain atrophy, drug concentration, extended interval dosing, natalizumab
note: © The Author(s) 2024. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/).
abstract: BACKGROUND: Extended interval dosing (EID) of natalizumab treatment is increasingly used in multiple sclerosis. Besides the clear anti-inflammatory effect, natalizumab is considered to have neuroprotective properties as well. OBJECTIVES: This study aimed to study the longitudinal effects of EID compared to standard interval dosing (SID) and natalizumab drug concentrations on brain atrophy. METHODS: Patients receiving EID or SID of natalizumab with a minimum radiological follow-up of 2 years were included. Changes in brain atrophy measures over time were derived from clinical routine 3D-Fluid Attenuated Inversion Recovery (FLAIR)-weighted magnetic resonance imaging (MRI) scans using SynthSeg. RESULTS: We found no differences between EID (n = 32) and SID (n = 50) for whole brain (-0.21% vs -0.16%, p = 0.42), ventricular (1.84% vs 1.13%, p = 0.24), and thalamic (-0.32% vs -0.32%, p = 0.97) annualized volume change over a median follow-up of 3.2 years. No associations between natalizumab drug concentration and brain atrophy rate were found. CONCLUSION: We found no clear evidence that EID compared to SID or lower natalizumab drug concentrations have a negative impact on the development of brain atrophy over time.
date: 2024-01-18
date_type: published
official_url: https://doi.org/10.1177/13524585231225855
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2141314
doi: 10.1177/13524585231225855
medium: Print-Electronic
lyricists_name: Barkhof, Frederik
lyricists_id: FBARK32
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Multiple Sclerosis Journal
event_location: England
citation:        Toorop, Alyssa A;    Noteboom, Samantha;    Steenwijk, Martijn D;    Gravendeel, Job W;    Jasperse, Bas;    Barkhof, Frederik;    Strijbis, Eva Mm;                 ... Killestein, Joep; + view all <#>        Toorop, Alyssa A;  Noteboom, Samantha;  Steenwijk, Martijn D;  Gravendeel, Job W;  Jasperse, Bas;  Barkhof, Frederik;  Strijbis, Eva Mm;  Rispens, Theo;  Schoonheim, Menno M;  van Kempen, Zoé LE;  Killestein, Joep;   - view fewer <#>    (2024)    Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.                   Multiple Sclerosis Journal        10.1177/13524585231225855 <https://doi.org/10.1177/13524585231225855>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10186117/1/toorop-et-al-2024-exploring-the-effects-of-extended-interval-dosing-of-natalizumab-and-drug-concentrations-on-brain.pdf